S. del Rio-Sancho1, D. Concas2, P. Oreste3, G. Zoppetti3, P.H. Briggs4, and Y. N. Kalia1
1School of Pharmaceutical Sciences. University of Geneva. 30 Quai Ernest Ansermet. 1211 Geneva, Switzerland
2Wezen Bio AG. Fondation pour Recherches Médicales, 64 Avenue de la Roseraie. 1205 Geneva, Switzerland
3Glycores 2000. Via Mac Mahon 43. 20155 Milan, Italy
4Alkhalediah Equine Hospital, Riyadh 11564, Kingdom of Saudi Arabia
The aim was to evaluate a novel diclofenac formulation designed to control mild-to-moderate inflammation and pain associated with orthopedic and soft tissue conditions in horses. Delivery from the new formulation was compared to that from a reference product (Surpass®) using skin from five healthy horses. Cumulative permeation and skin deposition were significantly increased with the new formulation. Mathematical modeling showed that this was due to a significant increase in drug partitioning into the skin.